Report Overview

The global ablation technology device market was pegged at US$ 8.4 billion in 2021 and is expected to witness a CAGR of 8.9% during the forecast period.

Market Fundamentals

Ablation is a minimally invasive procedure that is used to destroy (ablate) abnormal tissue or cause scarring on the tissue by vaporization, chipping, erosive processes, or other means. It is used in various areas such as for the treatment of cancer, cardiovascular diseases, gynecological diseases, cosmetic procedures, and pain management. The ablation procedure uses probes to discharge energy beams at the affected areas. The abnormal tissues can be destroyed using different techniques such as heat (radiofrequency ablation), extreme cold (cryoablation), lasers or chemicals, etc.

Market Dynamics

[125323]

The increasing prevalence of chronic diseases such as cancer, cardiovascular diseases (CVD), etc., coupled with the rising geriatric population is leading to increased use of ablation technologies. There is a significant rise in the demand for non-invasive or minimally invasive procedures, owing to its benefits such as quick recovery, lower risk of complications, shorter hospitalization, minimal pain, and smaller incisions. Ablation also helps the surgeon safely collect samples for the biopsy. The adoption of advanced technology has increased the accuracy of the devices with more portability and improved imaging system. These are some of the factors which are propelling the growth in the global ablation technology market. However, the present conventional therapies are effective and are used on large scaled. Lack of awareness about the advanced treatment mostly in developing countries, high risk associated with the ablation procedure, and stringent regulation for the approval of ablation devices are some of the factors restricting the growth of the market.

Market Ecosystem

The global ablation technology market has been analyzed from four perspectives: product, application, end user, and region. 

Ablation Technology Market by Product

[5243623]

Based on product type, the global ablation technology market is segmented into radiofrequency, cryoablation, laser, ultrasound, microwave, electrical and hydrothermal. The radiofrequency segment dominates the market with the largest market share in 2021. The large share of the market can be attributed to the increased use of radiofrequency ablation technology in the treatment of a vast number of conditions, such as cardiac diseases, cancer, chronic pain, and ophthalmic disease. In 90-98% of cases, radiofrequency ablation techniques are successful in treating arrhythmias. Moreover, the rising introduction of new and advanced products is also attributed to the growth of the segment in the market. For instance, in Nov 2020, Abbott announced the launch of the IonicRF™ Generator – a new device cleared by the U.S. FDA to deliver a non-surgical, minimally invasive treatment for the management of pain in the nervous system. The IonicRF Generator is a radiofrequency ablation device that uses heat to target specific nerves and block pain signals from reaching the brain.

Ablation Technology Market by Application

Based on application, the global ablation technology market is segmented into cancer treatment, cardiovascular treatment, gynecological treatment, cosmetic surgery, pain management, ophthalmologic, urological, orthopedic, and others. The cardiovascular segment dominates the market with the largest market share in 2021 owing to the increasing prevalence of cardiovascular diseases. According to WHO, cardiovascular diseases (CVDs) are the leading cause of death worldwide, with 17.9 million people dying due to cardiovascular diseases each year. Furthermore, rising R&D for atrial fibrillation and the growing adoption of ablation technology for the treatment of atrial fibrillation is also expected to boost the growth of the segment. According to the Heart Rhythm Society, 75,000 ablations take place every year for arterial fibrillation in the U.S. 

Ablation Technology Market by End User

Based on end user, the global ablation technology market is segmented into hospitals, ambulatory surgical centers, and medical spas. The hospitals segment dominated the market with a large market share in 2021. The large share of the hospitals can be attributed to the infrastructure, equipment, and experienced doctors in hospitals. Around 50% of all ablations takes place in hospitals.

Ablation Technology Market by Region

Based on region, the global ablation technology market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. North America dominated the global ablation technology market in 2021, followed by Europe. The large share of North America in the global ablation technology market can largely be attributed to the rising demand for non-invasive or minimally invasive procedures, and the rising prevalence of cancer and cardiovascular diseases. According to the American Cancer Society, an estimated 1.9 million new cancer cases were diagnosed in 2021.  Additionally, rising awareness regarding ablation technology in the region, the presence of developed health infrastructure, high healthcare expenditure, and rapid adoption of developed technology can also be attributed to the growth of the region.

Competitive Landscape

Some of the prominent players operating in the global ablation technology market are:

• Medtronic plc
• AngioDynamics Inc.
• Abbott Laboratories
• Boston Scientific Corporation
• Johnson & Johnson (Ethicon Inc.)
• CONMED Corporation
• Bausch & Lomb Incorporated
• Biotronik SE & Co. KG
• AtriCure Inc.
• Varian Medical Systems
• Olympus Corporation
• Dornier MedTech

Strategic Developments

• In July 2022, CardioFocus, Inc. announced its HeartLight X3 System a next-generation pulse field ablation system for the treatment of atrial fibrillation. The patents for this technology were filed in the same year and the company is expected to start its first human use in 2023
• In July 2022, Stereotaxis announced its CE Mark submission for its MAGiC catheter, a robotically navigated magnetic interventional ablation catheter that is used for cardiac ablation procedures
• In May 2022, Acutus Medical announced the completion of patient enrolment in the AcQForce Flutter Investigational Device Exemption (IDE) clinical trials. The trial intends to test the efficacy of the AcQBlate FORCE an ablation catheter used in the treatment of right atrial typical flutter

Frequently Asked Questions About This Report